imiquimod has been researched along with T-Cell Lymphoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cocozza, F; Gravisaco, MJ; Menay, F; Mongini, C; Sciullo, PD; Waldner, CI | 1 |
| Agarwal, K; Landrigan, A; Utz, PJ; Yiu, G | 1 |
| Beyeler, M; Dummer, R | 1 |
| Bazarbachi, A; Bonnet, PA; Deleuze-Masquéfa, C; El-Hajj, H; El-Sabban, ME; Hermine, O; Kfoury, Y; Lepelletier, Y; Moarbess, G | 1 |
1 review(s) available for imiquimod and T-Cell Lymphoma
| Article | Year |
|---|---|
[Standard and experimental therapy of cutaneous T-cell lymphoma].
Topics: Adrenal Cortex Hormones; Aminoquinolines; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell; Methotrexate; Photopheresis; Prednisone; PUVA Therapy; Radioisotope Teletherapy; Radiotherapy Dosage; Radiotherapy, High-Energy; Recombinant Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vincristine | 2003 |
3 other study(ies) available for imiquimod and T-Cell Lymphoma
| Article | Year |
|---|---|
Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Extracts; Cell Line, Tumor; Disease Models, Animal; Female; Graft vs Tumor Effect; Humans; Imiquimod; Lymphoma, T-Cell; Mice; Mice, Inbred BALB C; Toll-Like Receptor 7 | 2019 |
Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chemokine CCL5; Cytokines; Dose-Response Relationship, Drug; Humans; Imiquimod; Interleukin-10; Lymphoma, T-Cell; Mice; Oligodeoxyribonucleotides; Time Factors; Toll-Like Receptors | 2012 |
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Division; Cytochromes c; G2 Phase; Human T-lymphotropic virus 1; Humans; Imiquimod; Inflammation; Inhibitor of Apoptosis Proteins; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphocyte Activation; Lymphoma, T-Cell; Membrane Potential, Mitochondrial; NF-kappa B; Quinoxalines; Skin Neoplasms; Tumor Suppressor Protein p53 | 2008 |